Skip to main content

Table 5 Adjusted HRs of cardiovascular outcomes across the spectrum of FPG and NT-proBNP categories

From: The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study

FPG category

NT-proBNP

T1 (< 92 pg/ml)

T2 (92–335 pg/ml)

T3 (≥ 336 pg/ml)

 

n/N

HR (95% CI) *

n/N

HR (95% CI) *

n/N

HR (95% CI) *

P value for trend

MACCEs

       

 < 5.6 mmol/l

86/1533

Ref.

128/1486

1.18 (0.89–1.56)

302/1365

2.02 (1.55–2.65)

 < 0.001

 5.6–6.9 mmol/l

52/630

1.40 (0.99–1.98)

78/635

1.63 (1.19–2.24)

126/623

1.85 (1.36–2.50)

 < 0.001

 ≥ 7.0 mmol/l

43/490

1.37 (0.95–1.97)

84/534

1.96 (1.44–2.68)

171/660

2.33 (1.74–3.12)

 < 0.001

 P value for trend

 

0.932

 

0.013

 

 < 0.001

 

All-cause mortality

       

 < 5.6 mmol/l

19/1533

Ref.

36/1486

1.12 (0.64–1.97)

177/1365

2.77 (1.66–4.61)

 < 0.001

 5.6–6.9 mmol/l

8/630

0.96 (0.42–2.20)

17/635

1.23 (0.63–2.38)

73/623

2.61 (1.52–4.50)

 < 0.001

 ≥ 7.0 mmol/l

7/490

0.98 (0.41–2.33)

34/534

2.66 (1.49–4.72)

90/660

3.27 (1.92–5.57)

 < 0.001

 P value for trend

 

0.062

 

0.341

 

0.002

 
  1. *Estimates were adjusted for age, sex, BMI, NSTE-ACS status, previous hypertension, previous dyslipidemia, previous myocardial infarction, systolic blood pressure, heart rate, LVEF, eGFR, hs-CRP, LDL-C, smoking status, and in-hospital treatments (PCI, antiplatelet therapy, β-blocker, ACEI or ARB, and statins); Statistically significant estimates in bold
  2. Abbreviations see Table 1